Hansa Biopharma (Q4 update): Strong Quarter in Europe - Redeye

Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat of our estimate. IDEFIRIX sales amounted to SEK61m. The communication from the FDA about a potential priority review this month will be an important share catalyst.

Länk till analysen i sin helhet: https://www.redeye.se/research/1148786/hansa-biopharma-q4-update-strong-quarter-in-europe?utm_source=finwire&utm_medium=RSS